Arrowhead Pharmaceuticals (ARWR) Stock
Clinical stage biotech developing gene silencing liver drugs. Here's the price, business snapshot, and what's worth knowing about Arrowhead Pharmaceuticals in July 2026.
Arrowhead Pharmaceuticals (ARWR) is a clinical-stage biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. Using a proprietary delivery platform designed to silence specific genes, Arrowhead advances candidates aimed primarily at liver-related diseases and other conditions where gene knockdown may be therapeutic. The business model is R&D‑driven: value tends to be tied to clinical milestones, regulatory progress and partnerships rather than stable product revenue. Investors should note the binary nature of clinical outcomes, the time and capital typically required to bring experimental therapies to market, and the potential for significant share-price volatility around trial results and deal announcements. The company may partner or licence programmes to larger pharmaceutical groups to share development risk and access commercial expertise. This summary is for educational purposes only and not investment advice; individual suitability depends on personal circumstances and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Arrowhead Pharmaceuticals' stock, expecting it to rise from its current price.
Financial Health
Arrowhead Pharmaceuticals is doing well with strong revenue and cash flow, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ARWR
Blood Thinner Breakthrough Explained | Market Overview
Bayer's successful Phase III trial for its new blood thinner has demonstrated a significant reduction in stroke recurrence. This breakthrough positions the company favorably against competitors and highlights an investment opportunity in the evolving landscape of cardiovascular treatments.
Published: 6 February 2026
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: 21 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Progress in human trials can materially change valuation, so clinical read-outs are worth watching — though outcomes are binary and can be unpredictable.
RNAi platform focus
A platform approach can create multiple opportunities if delivery and safety perform well, but technical and regulatory hurdles remain.
Partnerships and deals
Collaborations with larger pharma can de‑risk development and provide milestones, yet deal terms and reliance on partners also shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
